BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schönland SO, Dreger P, de Witte T, Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 2012;47:895-905. [DOI: 10.1038/bmt.2011.152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Kollmer J, Weiler M, Purrucker J, Heiland S, Schönland SO, Hund E, Kimmich C, Hayes JM, Hilgenfeld T, Pham M, Bendszus M, Hegenbart U. MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. Neurology 2018;91:e625-34. [DOI: 10.1212/wnl.0000000000006002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
2 Kazman P, Vielberg MT, Pulido Cendales MD, Hunziger L, Weber B, Hegenbart U, Zacharias M, Köhler R, Schönland S, Groll M, Buchner J. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation. Elife 2020;9:e52300. [PMID: 32151314 DOI: 10.7554/eLife.52300] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
3 Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica 2017;102:1424-31. [PMID: 28522573 DOI: 10.3324/haematol.2016.163246] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
4 Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant 2019;54:508-18. [PMID: 30089901 DOI: 10.1038/s41409-018-0284-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 2016;128:594-602. [DOI: 10.1182/blood-2015-10-676361] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
6 Yilmaz A, Bauersachs J, Kindermann I, Klingel K, Knebel F, Meder B, Morbach C, Nagel E, Schulze-bahr E, aus dem Siepen F, Frey N. Diagnostik und Therapie der kardialen Amyloidose: Positionspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK). Kardiologe 2019;13:264-91. [DOI: 10.1007/s12181-019-00344-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
7 Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplant 2016;51:732-4. [PMID: 26726941 DOI: 10.1038/bmt.2015.326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Blank N, Hegenbart U, Schönland S. [Causes and treatment of systemic amyloidosis]. Z Rheumatol 2016;75:141-50. [PMID: 26768274 DOI: 10.1007/s00393-015-0024-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Zhao Q, Wang L, Song P, Li F, Zhou X, Yu Y, An Z, Wang X, Zhai Y. [Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone]. Zhonghua Xue Ye Xue Za Zhi 2016;37:283-7. [PMID: 27093989 DOI: 10.3760/cma.j.issn.0253-2727.2016.04.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Devine SM. Re-Examining the Role of High-Dose Chemotherapy in the Treatment of Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation 2014;20:14-9. [DOI: 10.1016/j.bbmt.2013.11.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cho H, Kim SJ, Shim CY, Hong GR, Ha JW, Kim YR, Yang WI, Chung H, Jang JE, Cheong JW, Min YH, Kim JS. Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. Leuk Res 2017;60:36-43. [PMID: 28648672 DOI: 10.1016/j.leukres.2017.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid 2014;21:202-10. [PMID: 25007036 DOI: 10.3109/13506129.2014.940457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
14 Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-7. [PMID: 23479568 DOI: 10.1182/blood-2012-12-473066] [Cited by in Crossref: 228] [Cited by in F6Publishing: 224] [Article Influence: 25.3] [Reference Citation Analysis]
15 Hora M, Carballo-Pacheco M, Weber B, Morris VK, Wittkopf A, Buchner J, Strodel B, Reif B. Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains. Sci Rep 2017;7:41515. [PMID: 28128355 DOI: 10.1038/srep41515] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
16 Lisenko K, Wuchter P, Hansberg M, Mangatter A, Benner A, Ho AD, Goldschmidt H, Hegenbart U, Schönland S. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. Biol Blood Marrow Transplant 2017;23:1870-8. [PMID: 28754546 DOI: 10.1016/j.bbmt.2017.07.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant 2019;54:1525-52. [PMID: 30953028 DOI: 10.1038/s41409-019-0516-2] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 29.3] [Reference Citation Analysis]
18 Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, Knebel F, Meder B, Morbach C, Nagel E, Schulze-Bahr E, Aus dem Siepen F, Frey N. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021;110:479-506. [PMID: 33459839 DOI: 10.1007/s00392-020-01799-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
19 Wang Q, Jiang F, Xu G. The pathogenesis of renal injury and treatment in light chain deposition disease. J Transl Med 2019;17:387. [PMID: 31767034 DOI: 10.1186/s12967-019-02147-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Landau HJ, Gertz MA, Comenzo RL. Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. Chichester: John Wiley & Sons, Ltd; 2015. pp. 724-41. [DOI: 10.1002/9781118416426.ch60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Muzaffar J, Katragadda L, Haider S, Abdallah AO, Anaissie E, Usmani SZ. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol 2013;130:146-9. [PMID: 23689541 DOI: 10.1159/000347036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Devine SM. Reprint of: Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis. Biol Blood Marrow Transplant 2014;20:S2-7. [PMID: 24429043 DOI: 10.1016/j.bbmt.2013.11.035] [Reference Citation Analysis]
23 Ikeda S, Hineno A, Yoshinaga T, Matsuo K, Suga T, Shiina T, Otsuki T, Hoshii Y. Sjögren syndrome-related plasma cell disorder and multifocal nodular AL amyloidosis: clinical picture and pathological findings. Amyloid 2019;26:225-33. [DOI: 10.1080/13506129.2019.1660636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Sivaraj D, Green MM, Ciftci AM, Zahid MF, Johns AA, Ross M, Gasparetto C. Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. Clin Lymphoma Myeloma Leuk 2016;16:e95-e100. [PMID: 27101986 DOI: 10.1016/j.clml.2016.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Dhakal B, Strouse C, D'souza A, Arce-lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and Abbreviated-Course Granulocyte Colony–Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation 2014;20:1926-31. [DOI: 10.1016/j.bbmt.2014.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. Cancer Med 2016;5:1464-72. [PMID: 27109862 DOI: 10.1002/cam4.725] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
27 Gratwohl A, Baldomero H, Passweg J. Hematopoietic stem cell transplantation activity in Europe: . Current Opinion in Hematology 2013;20:485-93. [DOI: 10.1097/moh.0b013e328364f573] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]